Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 1 (5)
P 2 (1)

Trial Status

Unknown4
Recruiting2
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT03938987Phase 1Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

NCT03774654Phase 1Active Not Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

NCT06581081Not ApplicableRecruitingPrimary

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

NCT06141304Phase 2UnknownPrimary

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

NCT05679687Phase 1Unknown

ThisCART19A Bridging to alloHSCT for R/R B-ALL

NCT04516551Phase 1UnknownPrimary

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

NCT03091933Phase 1Unknown

Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)

Showing all 7 trials

Research Network

Activity Timeline